We previously reported that glycemic control deteriorated in patients receiving atorvastatin, which is useful for the treatment of hypercholesterolemia in patients with type 2 diabetes. Pitavastatin has a strong lipid-lowering effect, comparable to that of atorvastatin, but it is unknown whether pitavastatin has an adverse influence on glycemic control. The aim of this study was to examine. The effects of three different statins (pravastatin, atorvastatin, and pitavastatin) on blood glucose and HbA1c levels in diabetic patients. Methods: We retrospectively compared glycemic control between groups receiving atorvastatin (10 mg/day, group A, n 99), pravastatin (10 mg/day, group Pr, n 85), and pitavastatin (2 mg/day, group Pi, n 95) from the start of treatment until 3 months later. Patients were excluded if the dosage of their antidiabetic drugs was changed, if their drug therapy was altered within 3 months before starting statin therapy, or if events occurred that could affect glycemic control such as hospitalization. Results: The subjects available for analysis were 74 patients from group A, 71 patients from group Pr, and 74 patients from group Pi. Arbitrary blood glucose levels increased from 147 51 mg/dL (mean SD) to 176 69 mg/dL in group A, but only changed minimally from 136 31 to 134 32 mg/dL in group Pr and from 155 53 to 154 51 mg/dL in group Pi. HbA1c increased from 7.0 1.1% to 7.4 1.2% in group A, while it was 6.9 0.9% versus 6.9 1.0% in group Pr, and 7.3 1.0% versus 7.2 1.0% in group Pi. There was no correlation between LDL-C and HbA1c (the change from baseline to 3 months) in any of the groups. Conclusion: The glycemic parameters only increased significantly in group A, suggesting that pitavastatin and pravastatin did not have an adverse influence on glycemic control in type 2 diabetic patients. 
Introduction
HMG-CoA reductase inhibitors are often administered for the treatment of hypercholesterolemia in patients with type 2 diabetes. Subgroup analysis of the Atorvastatin, a lipophilic HMG-CoA reductase inhibitor, has potent LDL-cholesterol-lowering activity and is frequently administered for the treatment of hypercholesterolemia associated with type 2 diabetes mellitus. In the recent CARDS study 5) , atorvastatin was shown to inhibit the development of cardiovascular events in diabetic patients. However, the ASPEN study did not find any significant beneficial effect of atorvastatin in such patients 6) . Thus, disagreement persists as to which statins should be used for the treatment of dyslipidemia in diabetics.
It has been a matter of recent concern whether or not atorvastatin causes a deterioration of glycemic control. Sasaki et al. have comprehensively reviewed the adverse effect of statins on glucose metabolism 7) . There are only a few relevant clinical trials. High-dose atorvastatin therapy was associated with worsening of glycemic control in one trial 8) . In Japan, there have been a few case reports and some clinical trials that have indicated a potential adverse effect of atorvastatin, although these studies were small in size and had a short follow-up period. In addition, we previously reported that standard doses of atorvastatin adversely affect glycemic control, unlike pravastatin 9) . Pitavastatin is an HMG-CoA reductase inhibitor that is commonly used in Japan and has a powerful lipid-lowering effect. The reduction of LDL-C by pitavastatin is comparable to that achieved with atorvastatin, while pitavastatin also raises the level of highdensity lipoprotein cholesterol (HDL-C) 10) . However, its effect on glycemic control has not been investigated clinically. The aim of the present study was to compare the effects of three different statins (pravastatin, atorvastatin, and pitavastatin) on blood glucose and HbA1c levels in diabetic patients with hyperlipidemia at the dosages currently used in Japan.
Subjects and Methods
Patients with type 2 diabetes mellitus complicated by hyperlipidemia and receiving an HMG-CoA reductase inhibitor who were treated at Yokohama City University Medical Center and Kanazawa Medical Clinic were enrolled in a retrospective study. Specifically, patients in this study began treatment with of one of three different statins atorvastatin (group A), pravastatin (group Pr), or pitavastatin (group Pi) between January 2000 and July 2006.
Which statin was given was the decision of the physician in charge of the individual patient. Patients whose HbA1c had changed more than 10% within the preceding 3 months were excluded. As shown in Fig. 1 , HbA1c at baseline and 3 months before initiation of the study did not differ significantly between groups.
There were 99 patients in group A (45 men and 54 women; mean age, 59.4 years); 85 patients in group Pr (38 men and 47 women; mean age, 65.9 years); and 95 patients in group Pi (46 men and 49 women; mean age, 63.0 years). Baseline characteristics of the patients are shown in Table 1 . First, it was determined whether or not patients had required an increase or reduction in the doses of antidiabetic drugs (insulin and oral hypoglycemic agents) during the first 3 months of statin therapy. Only patients who did not require any changes of drug doses were then assessed for changes in random blood glucose and HbA1c levels during this 3-month period of statin therapy. Patients were excluded from the study if there was any change in the doses of their antidiabetic drugs, if their medications had been altered within 3 months prior to initiation of statin therapy, and if they were new patients attending the diabetes education program for the first time. Patients who experienced events that could alter glycemic control such as hospitalization or development of intercurrent disorders during the 3-month clinical observation period were also excluded. Medications that are known to influence glucose tolerance or lipid metabolism were not added or withdrawn during the study. As shown in Table 2 , the number of subjects ultimately included in the statistical analyses was 74 patients in group A, 71 patients in group Pr, and 74 patients in group Pi. Although no significant difference was found between groups in age, body weight, or history of coronary artery disease, prior treatment with other antilipemic drugs was more frequent in groups A and Pi. A statement of institutional approval of the study in accordance with the Declaration of Helsinki was obtained.
Blood samples were withdrawn from the antecubital vein. HbA1c levels were measured by high performance liquid chromatography and plasma glucose levels were measured using the glucose oxidase method. Serum total cholesterol, Triglyceride (TG), and HDLcholesterol levels were measured by standard enzymatic methods. The LDL-C level was measured with direct LDL-cholesterol assay kits (choletest-LDL, SEKISUI MEDICAL CO) at SRL. Inc.
Values are expressed as the mean SD. Statistical analyses used paired t tests or repeated-measures ANOVAs. Others: other factors that could affect glycemic control, such as hospitalization or development of intercurrent disorders.
Results
The increase or reduction of antidiabetic drug doses during the 3-month period after initiation of statin administration is shown in Table 2 . During this 3-month clinical observation period, 19 group A patients required a dose increase, 1 required a dose reduction, and 5 required other modifications (i.e.; patients with a reduction of the insulin dose, reflecting the addition of an -GI, in whom overall assessment was difficult). In group Pr, 12 patients required a dose increase, none required a dose reduction, and 2 required other modifications. In group Pi, 15 patients required a dose increase and 4 required other modifications. No statistically significant differences in dosing changes were found between the three groups. Other medications that could possibly affect glucose metabolism, such as antihypertensive drugs, did not differ significantly between the three groups ( Table 1) .
There were no changes of antidiabetic drug doses for 74 patients in group A, 70 patients in group Pr, and 76 patients in group Pi. In these patients, the arbitrary blood glucose level changed from 147 51 to 176 69 mg/dL in group A (p 0.001), from 136 31 to 134 32 mg/dL in group Pr, and from 155 53 to 154 51 mg/dL in group Pi (Fig. 1A) . HbA1c changed from 7.0 1.1% to 7.4 1.2% in group A (p 0.001), from 6.9 0.9% to 6.9 1.0% in group Pr, and from 7.3 1.0% to 7.2 1.0% in Group Pi (Fig. 1B) . Only group A showed a significant increase of both variables, and there were significantly greater changes of the values in group A than in group Pr or Pi (p 0.01).
The plasma lipid and lipoprotein concentrations immediately before and 3 months after starting statin therapy are shown in 4 10.0 kg in group P, and from 61.3 11.4 to 61.9 12.6 kg in group Pi, with no significant difference of body weight changes between the groups.
Total cholesterol and TG levels were higher in group A, a difference that could have affected the blood glucose concentration. We therefore divided groups A and Pi into a subgroup with lower total cholesterol or TG levels than in group Pr and another subgroup with equal or higher total cholesterol or TG levels than in group Pr. In the subgroup of patients from group A with equal/higher total cholesterol levels than in group Pr ( ≥ 226 mg/dL), HbA1c changed from 7.0 1.2% to 7.4 1.4% compared with a change from 7.2 1.1% to 7.0 0.9% in the subgroup from group Pi. In the subgroup from group A with a total cholesterol level 226 mg/dL, HbA1c increased significantly from 7.0 0.9% to 7.4 1.0% compared with a change from 7.2 0.9% to 7.3 1.2% in the subgroup from group Pi. No significant differences of these changes were noted between the subgroups.
In the subgroup of group A patients with a TG level equal/higher than that in group Pr ( ≥ 144 mg/ dL), HbA1c increased significantly from 7.1 1.2% to 7.5 1.3% compared with a change from 7.2 1.0% to 7.1 1.2% in the subgroup from group Pi. In the subgroup from group A with a TG level 144 mg/dL, HbA1c rose significantly from 6.9 1.0% to 7.3 1.2% compared with no change (7.2 1.0% versus 7.2 1.2%) in the group Pi subgroup. No significant differences of these changes were evident between the subgroups ( Table 4) . We also studied the correlation between LDL-C and HbA1c (changes from baseline to 3 months). Scatter plots showed that LDL-C and HbA1c were neither positively nor negatively correlated in each group (Fig. 2) .
Discussion
We examined changes of glycemic control over 3 months after the initiation of treatment with three different statins. No significant intergroup differences in the changes of antidiabetic drug doses were noted. However, assessment of the patients without dose changes revealed a significant increase in random blood glucose and HbA1c levels after 3 months in the patients receiving atorvastatin.
Recent studies have shown that pitavastatin has multiple effects, such as reducing inflammation 11) and the generation of reactive oxygen species 12) , improving endothelial function 13) , increasing nitric oxide production 14) , inhibiting cell adhesion 15) , inhibiting the contraction of smooth muscle cells 16) , and promoting apolipoprotein (apo) A-production 17) . Pitavastatin has a potent lipid-lowering effect, and the reduction of LDL-C is comparable to that achieved with atorvastatin 10) . Concerning glycemic control, Kawai et al. 18) recently reported that pitavastatin had no effect on plasma glucose or HbA1c levels, but they did not compare pitavastatin with other statins. Therefore, we carried out a retrospective direct comparison of the influence of three different statins on glycemic control in patients with type 2 diabetes. We found that random blood glucose and HbA1c levels increased after 3 months of treatment in group A, but not in group Pr or group Pi.
Why only atorvastatin, and not pitavastatin or pravastatin, affects glycemic control is not clear. Cytochrome P450-mediated metabolic pathways might be involved in these differences 19) . Metabolism of pitavastatin by the cytochrome P450 (CYP) system is minimal, and principally occurs via CYP 2C9 with little involvement of the CYP 3A4 isoenzyme. This could reduce the risk of interactions between pitavastatin and other drugs known to inhibit CYP enzymes. Statins can compromise glycemic control by decreasing levels of metabolites such as isoprenoid, farnesylpyrophosphate, geranylgeranyl pyrophosphate, and ubiquion (CoQ10). Isoprenoid is known to enhance glucose uptake by upregulating the membrane transporter protein glucose transporter 4 (Glut4), which has a role in glucose uptake by adipocytes 20) . Quite recently, atorvastatin (but not pravastatin) was shown to inhibit adipocyte maturation and GLUT4 expression by blocking isoprenoid biosynthesis, and it was also found to Subjects were treated with atorvastatin, pitavastatin, and pravastatin for 3 months. A scatter plot illustrates the changes of LDL-C and HbA1c from baseline.
impair glucose tolerance 21) . Statins have also been reported to modify insulin secretion. Yada et al. reported that simvastatin, but not pravastatin, inhibits glucose-induced insulin secretion through a blockade of L-type Ca 2 channels in isletcells 22) . In addition, atorvastatin was reported to impair insulin secretion 23) . The suppressive effect on insulin secretion might be due to the cytotoxicity of lipophilic statins for -cells or activation of SREBPs by statins. Differing effects of statins could reflect relatively selective interactions between a certain statin and the specific target tissue or cell.
We found that the total cholesterol and TG levels after 3 months of treatment were significantly higher in group A than in group Pr or group Pi. As a high TG level is frequently associated with insulin resistance 24) , these higher lipid levels may have affected blood glucose. To compensate for this possible influence, we analyzed changes of blood glucose and HbA1c levels after dividing groups A and Pi into subgroups with higher total cholesterol and TG levels than group Pr, or with similar total cholesterol and TG levels to group Pr. We found that HbA1c increased in group A irrespective of the changes in the total cholesterol or TG level. Therefore, total cholesterol and TG levels had less influence on glucose metabolism than the other parameters.
This study was retrospective and subjects were chosen from among patients for whom medication was initiated during a given time interval. This could give rise to bias between the groups with respect to prior lipid-lowering therapy before the current study period. More patients in groups A and Pi had previously received other drugs. Among them, 28 patients (the largest number) changed from atorvastatin to another study drug. Furthermore, 8 of these 28 patients required an increase in dose of antidiabetic drugs after changing to pitavastatin, no patient had a dose reduction, and 1 was not assessable. Among 20 patients who had no antidiabetic drug dose increases or reductions, HbA1c showed no significant decrease from the preadministration value of 7.4 1.0% to 7.2 0.9% at 3 months, while random blood glucose levels decreased from 167 55 to 156 52 mg/dL (also not significant). These findings supported the impression that atorvastatin interferes with glycemic control more than pitavastatin.
Our results showed that pitavastatin markedly lowers LDL cholesterol levels while not disrupting glycemic control in patients with diabetes. Previous largeand smaller-scale studies have highlighted the importance of strict lipid control in diabetic patients to inhibit the development of cardiovascular disease.
Recent guidelines recommended lower target levels of LDL-cholesterol in diabetics 25) . Numerous studies have demonstrated the strong cholesterol-lowering activity of atorvastatin, consistent with the present findings. Atorvastatin has also been reported to inhibit cardiovascular events 5) . Achievement of the current target for LDL-cholesterol requires a highly effective statin, such as atorvastatin or pitavastatin. In our study, the LDLcholesterol level attained with pitavastatin was comparable to that achieved with atorvastatin, but pitavastatin did not adversely affect glycemic control. Thus, pitavastatin may be more suitable for the treatment of hyperlipidemia in patients with type 2 diabetes.
Of course, careful observation of clinical status to detect any deterioration in glucose tolerance remains important when administering pitavastatin until conclusive evidence concerning its effects on the blood glucose concentration has been obtained. The discrepancies among previous studies may be attributable to the effects of different conditions during the observation period. Blood glucose is influenced by multiple lifestyle-related factors, especially diet and exercise. To understand why glycemic control deteriorates with atorvastatin therapy will require the investigation of a large number of patients to identify the mechanism involved and exclude confounding variables.
Conclusion
Atorvastatin and pitavastatin both show a potent cholesterol-lowering effect, but caution is required when prescribing atorvastatin to diabetics because of its influence on glycemic control.
